Antithrombin(H) concentrate infusions are safe and effective in patients with thermal injuries

Journal of Burn Care and Rehabilitation

Volumn 21, Issue 2, 2000, Pages 115-127

  Kowal Vern, Areta ^a   McGill, Victoria ^a   Walenga, Jeanine M ^a   Gamelli, Richard L ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; THROMBATE; UNCLASSIFIED DRUG;

ADULT; ANTITHROMBIN DEFICIENCY; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MALE; PILOT STUDY; SKIN AUTOGRAFT; THERMAL INJURY; WOUND HEALING;

EID: 0034064936     PISSN: 02738481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004630-200021020-00007     Document Type: Article

References (56)

1. Riker AI, Gamelli RL. Vascular complications after femoral artery catheterization in burn patients. J Trauma 1996;41: 904-5.
2. Heideman M. A shared effect of abscesses and nonviable tissue influencing the development of sepsis and acute respiratory distress syndrome. Acta Chir Scand Suppl 1982;508:295-302.
3. McLean NR, Ellis H. How does sepsis promote thrombosis in microvascular anastomoses? Br J Plast Surg 1989;42:314-7.
4. Müller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost 1989;15:58-87.
5. Geerts WH. Thromboembolism in trauma: the problem and its prevention. N Engl J Med 1994;331:1601-6.
6. Chang P, Murray DJ, Olson JD, Pennell BJ, Lewis RW, Kealey GP. Analysis of changes in coagulation factors after postoperative blood loss in burn and non-burn patients. Burns 1995;21:432-6.
7. Tweddell JS, Waymack JP, Warden GD, Law EJ, Jenkins M, Alexander JW. Hematuria in the burned child. J Pediatr Surg 1987;22:899-903.
8. Wells S, Sissons M, Hasleton PS. Quantitation of pulmonary megakaryocytes and fibrin thrombi in patients dying from burns. Histopathology 1984;8:517.
9. Choctaw WT, Fujita C, Zawacki BE. Prevention of upper gastrointestinal bleeding in burn patients. Arch Surg 1980;115:1073-6.
10. Prasad JK, Thompson PD, Feller I. Gastrointestinal haemorrhage in burn patients. Burns 1984;11:104-10.
11. Robb H. Dynamics of the microcirculation during a burn. Arch Surg 1967;94:776-89.
12. Order SE, Mason AD Jr, Walker HL, Lindberg RF, Switzer WE, Moncrief JA. The pathogenesis of second and third degree burns and conversion to full thickness injury. Surg Gynecol Obstet 1965;120:983-91.
13. Cotran RS, Remensnyder JP. The structural basis of increased vascular permeability after graded thermal injury - light and electron microscopic studies. Ann NY Acad Sci 1968;150:495-509.
14. Kowal-Vern A, Gamelli RL, Walenga JM, Hoppensteadt D, Sharp-Pucci M-M, Schumacher HR. The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical state. J Trauma 1992;33:50-7.
15. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998;91: 3527-61.
16. Penner JA. Antithrombin's role in the management of trauma. Biomed Prog 1998;11:7-11.
17. Penner JA. Disseminated intravascular coagulation in patients with multiple organ failure of non-septic origin. Semin Thromb Hemost 1998;24:45-52.
18. Cirino G, Cicala C, Bucci MR, Sorrentino L, Maraganore JM, Stone SR. Thrombin functions as an inflammatory mediator through the activation of its receptor. J Exp Med 1996;183:821-7.
19. Frebelius S, Hedin U, Swedenborg J. Thrombogenicity of the injured vessel wall-role of antithrombin and heparin. Thromb Hemost 1994;71:147-53.
20. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998;24:19-26.
21. Penner JA. Antithrombin deficiency in special clinical syndromes - part II: trauma/burns. Semin Hematol 1995;32:42-8.
22. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost 1998;24:27-32.
23. Biffl WL, Moore EE, Moore FA, Peterson VM. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg 1996;224:647-64.
24. Kowal-Vern A, Walenga JM, Hoppensteadt D, Sharp-Pucci M-M, Gamelli RL. Interleukin-2 and interleukin-6 in relation to burn wound size in the acute phase of thermal injury. J Am Coll Surg 1994;178:357-62.
25. Rodriguez JL, Miller CG, Garner WL, TillGO, Guerrero P, Moore NP, et al. Correlation of the local and systemic cytokine responses with clinical outcome following thermal injury. J Trauma 1993;34:684-95.
26. Jesty J, Lorenz A, Rodriguez J, Wun T-C. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. Blood 1996;87:2301-7.
27. Rapaport SI, Rao VM. The tissue factor pathway: how it has become a "prima ballerina." Thromb Haemost 1995;74:7-17.
28. Nemerson Y. Tissue factor: then and now. Thromb Haemost 1995;74:180-4.
29. Bombelli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997;90:2429-42.
30. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemostas 1995;74:90-3.
31. Olliver V, Bentolila S, Chabbat J, Hakim J, de Prost D. Tissue Factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998;91:2698-703.
32. Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemost 1998;24:3-18.
33. Reeder LB, Ferguson MK. Endothelin-1 synthesis and receptor-mediated activity in porcine lymph vessels. Surg Res 1996;63:215-9.
34. Kowal-Vern A, Walenga JM, Sharp-Pucci M-M, Hoppensteadt D, Gamelli RL. Postburn edema and related changes in interleukin-2, leukocytes, platelet activation, endothelin-1, and Clesterase inhibitor. J Burn Care Rehabil 1997;18:99-103.
35. Kowal-Vern A, Sharp-Pucci M-M, Walenga JM, Dries D, Gamelli RL. Trauma and thermal injury: comparison of hemostatic and cytokine changes in the acute phase of injury. J Trauma 1998;44:325-9.
36. Cohn EJ, Strong LE, Hughes WL Jr, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946;68:459-75.
37. Wisecarver JL. Disseminated intravascular coagulation with multiple arterial thromboses responding to antithrombin III concentrate infusion. Thromb Res 1989;54:709-17.
38. Vinazzer HA. Antithrombin III in shock and disseminated intravascular coagulation. Clin Appl Thromb Hemost 1995;1:62-5.
39. Lechner K, Kyrle PA. Antithrombin III concentrates - are they clinically useful? Thromb Haemost 1995;73:340-8.
40. Jochum M. Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin Hematol 1995;32:19-32.
41. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind placebo controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882-8.
42. Maki M. Antithrombin III: recent advances in obstetrical disseminated intravascular coagulation. Biomed Prog 1992; 5:5-8.
43. Obertacke U, Kleinschmidt C, Jochum M, Badenheuer M, Dresing K, Eisold C, et al. Reduction of shock-related complications and pulmonary microvascular permeability by continuous application of antithrombin III (140% serum activity) for 4 days after trauma - preliminary results of a prospective clinical study [abstract]. Circ Shock 1993;Suppl 1:41.
44. Takahashi H. Antithrombin III in the treatment of disseminated intravascular coagulation. Biomed Prog 1992;5:9-10.
45. Smith JK, Winkelman L, Evans DR, Haddon ME, Sims G. A pasteurized antithrombin III concentrate for clinical use. Vox Sang 1985;48:325-31.
46. Menache D, O'Malley JP, Schorr JB, Wagner B, Williams C. Cooperative study group: evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 1990;75:33-9.
47. Makris M. Safety of antithrombin III concentrate. Blood 1990;76:649-50.
48. Redens TB, Emerson TE. Antithrombin III treatment limits disseminated intravascular coagulation in endotoxemia. Circ Shock 1989;28:49-58.
49. Kessler CM, Tang ZC, Jacobs HM, Szymanski LM. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997;89:4393-401.
50. Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood 1998;91:2005-9.
51. Martinez R, Kowal-Vern A, Reddy V, McGill V, Pyle J, Gamelli RL. Cutaneous cellular infiltrates in thermally injured skin [abstract]. Shock Suppl 2 1997;7:18.
52. Inthorn D, Hoffmann JN, Hard WH, Muhlbayer D, Jochum M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 1998;10:90-6.
53. Fan Z, Larson PJ, Bognacki J, Raghunath PN, Tomaszewski JE, Kuo A, et al. Tissue Factor regulates plasminogen binding and activation. Blood 1998;91:1987-98.
54. Lenich C, Liu J-N, Gurewich V. Thrombin stimulation of platelets induces plasminogen activation, mediated by endogenous urokinase type plasminogen activator. Blood 1997;90:3579-86.
55. Danielsson P, Nilsson L, Nettelblad H, Sjoberg F. Is there a need for antithrombin III substitution early after burn injury? Burns 1997;23:300-5.
56. Chang W-SW, Harper PL. Commercial antithrombin concentrate contains inactive L-forms of antithrombin. Thromb Hemost 1997;77:323-8.